Wall Street brokerages expect that ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) will report earnings per share of ($0.56) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for ACADIA Pharmaceuticals’ earnings. The highest EPS estimate is ($0.53) and the lowest is ($0.58). ACADIA Pharmaceuticals reported earnings of ($0.72) per share in the same quarter last year, which would indicate a positive year over year growth rate of 22.2%. The firm is scheduled to announce its next earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that ACADIA Pharmaceuticals will report full-year earnings of ($1.83) per share for the current fiscal year, with EPS estimates ranging from ($2.00) to ($1.63). For the next year, analysts anticipate that the firm will post earnings of ($0.73) per share, with EPS estimates ranging from ($1.27) to ($0.31). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that cover ACADIA Pharmaceuticals.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.03. The company had revenue of $43.56 million for the quarter, compared to analysts’ expectations of $45.30 million. ACADIA Pharmaceuticals had a negative net margin of 231.71% and a negative return on equity of 73.02%.
In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 36,558 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $32.39, for a total transaction of $1,184,113.62. Following the transaction, the executive vice president now owns 83,734 shares of the company’s stock, valued at approximately $2,712,144.26. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Laura Brege sold 25,000 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $30.06, for a total transaction of $751,500.00. Following the transaction, the director now directly owns 15,000 shares in the company, valued at approximately $450,900. The disclosure for this sale can be found here. In the last three months, insiders have sold 135,879 shares of company stock worth $4,175,649. Insiders own 22.25% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. Earnest Partners LLC bought a new position in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $133,000. Turner Investments LLC bought a new position in shares of ACADIA Pharmaceuticals during the 3rd quarter worth approximately $188,000. Steward Partners Investment Advisory LLC bought a new position in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $200,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of ACADIA Pharmaceuticals by 43.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,670 shares of the biopharmaceutical company’s stock worth $214,000 after buying an additional 1,710 shares in the last quarter. Finally, State of Alaska Department of Revenue bought a new position in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $219,000. 96.25% of the stock is currently owned by hedge funds and other institutional investors.
ACADIA Pharmaceuticals (ACAD) opened at $24.98 on Wednesday. The stock has a market cap of $3,228.53, a PE ratio of -10.63 and a beta of 3.53. ACADIA Pharmaceuticals has a 1 year low of $22.35 and a 1 year high of $41.20.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.